$1,318.00
This Market Spotlight report covers the Endometriosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Endometriosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 GnRH analogs
9 Progestins
9 Combined oral contraceptives
9 Non-steroidal anti-inflammatory drugs
9 Danocrine
10 Surgery
11 EPIDEMIOLOGY
13 MARKETED DRUGS
16 PIPELINE DRUGS
21 RECENT EVENTS AND ANALYST OPINION
21 Relugolix for Endometriosis (June 23, 2020)
23 Relugolix for Endometriosis (April 22, 2020)
26 Relugolix for Endometriosis (October 31, 2019)
28 Proellex (Oral) for Endometriosis (June 25, 2019)
30 KEY UPCOMING EVENTS
31 PROBABILITY OF SUCCESS
32 LICENSING AND ASSET ACQUISITION DEALS
32 Myovant Licenses Ex-US Relugolix Rights To Gedeon Richter
33 REVENUE OPPORTUNITY
34 CLINICAL TRIAL LANDSCAPE
35 Sponsors by status
36 Sponsors by phase
37 Recent events
38 BIBLIOGRAPHY
38 Prescription information
39 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of endometriosis, 2019–28
16 Figure 2: Overview of pipeline drugs for endometriosis in the US
16 Figure 3: Pipeline drugs for endometriosis, by company
17 Figure 4: Pipeline drugs for endometriosis, by drug type
17 Figure 5: Pipeline drugs for endometriosis, by classification
23 Figure 6: Relugolix for Endometriosis (June 23, 2020): Phase III – SPIRIT 1
26 Figure 7: Relugolix for Endometriosis (April 22, 2020): Phase III – SPIRIT 2
30 Figure 8: Key upcoming events in endometriosis
31 Figure 9: Probability of success in the endometriosis pipeline
34 Figure 10: Clinical trials in endometriosis
34 Figure 11: Top 10 drugs for clinical trials in endometriosis
35 Figure 12: Top 10 companies for clinical trials in endometriosis
35 Figure 13: Trial locations in endometriosis
36 Figure 14: Endometriosis trials status
37 Figure 15: Endometriosis trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of endometriosis, 2019–28
14 Table 2: Marketed drugs for endometriosis
18 Table 3: Pipeline drugs for endometriosis in the US
21 Table 4: Relugolix for Endometriosis (June 23, 2020)
24 Table 5: Relugolix for Endometriosis (April 22, 2020)
27 Table 6: Relugolix for Endometriosis (October 31, 2019)
28 Table 7: Proellex (Oral) for Endometriosis (June 25, 2019)
33 Table 8: Historical global sales, by drug ($m), 2015–19
33 Table 9: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!